JAK-IN-30
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED).
For research use only. We do not sell to patients.
- CAS No.: 2891469-99-9
- Formula: C19H26N8S
- Molecular Weight:398.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13315A
MontelukastCysLT1 Antagonist -
HY-10411
AZ960JAK2 Inhibitor -
HY-108264
TCS 21311JAK3 Inhibitor -
HY-141633
Sucrose monolaurateSurfactant -
HY-13315AR
Montelukast (Standard)CysLT1 Antagonist -
HY-B1397C
Cyclizine hydrochlorideH1 Receptor Antagonist -
HY-14648A
Dexamethasone acetateCorticosteroid Ester -
HY-15166
(E/Z)-ZotiraciclibCDK/JAK2/FLT3 Inhibitor -
HY-10411R
AZ960 (Standard)Reference Standard -
HY-108264R
TCS 21311 (Standard)Reference Standard -
HY-105713
SulochrinAntimicrobial Agent -
HY-B0553S
Methazolamide-d6Stable Isotope
Biological Activity
Description
IC50 & Target
[1]|
JAK1 15 nM (IC50) |
JAK2 2 nM (IC50) |
JAK3 18 nM (IC50) |
Tyk2 2 nM (IC50) |
Chemical Information
-
CAS No. 2891469-99-9
-
Molecular Weight 398.53
-
Formula C19H26N8S
-
SMILES
N#CCC1(N2CCN(CC2)C)CN(C1)C(N=C3NC4=CC(C)=NS4)=C(C=N3)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Gordhan HM, et al. Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility. J Med Chem. 2023 Jul 13;66(13):8929-8950. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JAK-IN-30 Related Classifications
HY-154994 Related Classifications
Powered by Bioz